For the quarter ending 2025-09-30, DNABW had -$448,783K decrease in cash & cash equivalents over the period. -$131,041K in free cash flow.
| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -232,012 |
| Depreciation and amortization | 45,327 |
| Stock-based compensation | 60,519 |
| Goodwill impairment | 0 |
| Impairment of right-of-use asset | 0 |
| Loss on investments | -275 |
| Loss on deconsolidation of subsidiary | 0 |
| Change in fair value of notes receivable | -5,685 |
| Change in fair value of warrant liabilities | 0 |
| Change in fair value of contingent consideration | 4,232 |
| Non-cash lease expense | 22,449 |
| Non-cash in-process research and development | 0 |
| Accretion of discount on marketable securities | 2,502 |
| Other non-cash activity | -1,611 |
| Changes in operating assets and liabilities | -345 |
| Prepaid expenses and other current assets | 70 |
| Operating lease right-of-use assets | -3,814 |
| Other non-current assets | 38 |
| Accounts payable, accrued expenses and other current liabilities | 16,991 |
| Deferred revenue | -27,209 |
| Operating lease liabilities, current and non-current | -18,793 |
| Other non-current liabilities | 4,459 |
| Net cash used in operating activities | -123,381 |
| Purchases of marketable debt securities | 401,838 |
| Maturities of marketable debt securities | 73,599 |
| Purchases of property and equipment | 7,660 |
| Business acquisition | 0 |
| Proceeds from sales of marketable securities | 0 |
| Proceeds from sale of equipment | 0 |
| Other | -511 |
| Net cash used in investing activities | -335,388 |
| Proceeds from atm offering | 10,317 |
| Payment of issuance costs related to atm offering | 355 |
| Proceeds from exercise of stock options | 0 |
| Principal payments on finance leases | 329 |
| Contingent consideration payment | 0 |
| Other | 0 |
| Net cash provided by (used in) financing activities | 9,633 |
| Effect of foreign exchange rates on cash and cash equivalents | 353 |
| Net decrease in cash, cash equivalents and restricted cash | -448,783 |
| Cash and cash equivalents at beginning of period | 605,743 |
| Cash and cash equivalents at end of period | 156,960 |
Ginkgo Bioworks Holdings, Inc. (DNABW)
Ginkgo Bioworks Holdings, Inc. (DNABW)